I wonder these things myself. But I’m not expecting a big bump from the “Pre-Print”. I think that the major points have already been announced in PRs. The Pre-Print is very important because it’s additional validation and it will contain a lot of detailed information. However, the two things that I expect to have an impact on share price are grant announcements and/or announcements related to human trials. Of course the really “big bump” will be when positive results are announced from Phase 2 for Covid.

There are of course any number of other potential announcements that could happen. For instance, the RBL could announce that Brilacidin also worked against the flu and/or HIV and/or Zika and/or herpes and/or Ebola and/or any number of other viral plagues.